Supplemental Guarantor and Non-Guarantor Financial Information (Details 1) (USD $)	3 Months Ended																	12 Months Ended
	Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2012		Sep. 30, 2012		Jun. 30, 2012		Mar. 31, 2012		Dec. 31, 2011	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011
Condensed Consolidating Statement of Comprehensive Income
Total net revenues	$ 486,137,000		$ 410,492,000		$ 414,424,000		$ 415,591,000		$ 425,017,000		$ 424,444,000		$ 427,691,000		$ 435,652,000			$ 1,726,644,000		$ 1,712,804,000		$ 1,798,778,000
Cost of services sold																		942,180,000		908,741,000		948,455,000
Gross profit	204,955,000		190,014,000		195,477,000		194,018,000		195,763,000		200,555,000		204,954,000		202,791,000			784,464,000		804,063,000		850,323,000
Selling, general and administrative expenses																		(701,716,000)		(655,766,000)		(730,407,000)
Dividend income																		0		0		8,590,000	[1]
Gain on sale of assets and businesses, net									2,600,000				5,400,000					0		8,014,000		1,061,000
Goodwill, intangibles and other long-lived asset impairment																	(643,300,000)	(610,436,000)	[2]	(19,132,000)	[2]	(643,305,000)	[2]
Interest expense and other, net																		(110,384,000)	[3]	(89,947,000)	[3]	(88,610,000)	[3]
Equity in earnings (loss) of subsidiaries																		0		0		0
(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix	(443,844,000)	[4]	6,852,000		11,392,000		(212,472,000)	[4]	18,510,000	[5]	(2,678,000)	[4]	23,818,000	[5]	7,582,000			(638,072,000)		47,232,000		(602,348,000)
Income tax benefit (expense)																		39,565,000		(17,251,000)		75,768,000
Equity in net (loss) earnings of CareCentrix																		0		(2,301,000)		68,381,000
(Loss) income from continuing operations																		(598,507,000)		27,680,000		(458,199,000)
Discontinued operations, net of tax																		0		0		8,315,000
Net (loss) income	(401,884,000)	[4],[6]	3,720,000	[6]	6,347,000	[6]	(207,177,000)	[4],[6]	8,570,000	[5],[6],[7]	(523,000)	[4],[6]	13,909,000	[5],[6]	4,840,000	[6]		(598,507,000)		27,680,000		(449,884,000)
Less: Net income attributable to noncontrolling interests																		(487,000)		(884,000)		(641,000)
Net (loss) income attributable to Gentiva shareholders																		(598,994,000)		26,796,000		(450,525,000)
Total comprehensive (loss) income																		(598,507,000)		27,680,000		(450,362,000)
Gentiva Health Services, Inc. [Member]
Condensed Consolidating Statement of Comprehensive Income
Total net revenues																		0		0		0
Cost of services sold																		0		0		0
Gross profit																		0		0		0
Selling, general and administrative expenses																		0		0		0
Dividend income																						0
Gain on sale of assets and businesses, net																				0		0
Goodwill, intangibles and other long-lived asset impairment																		0		0		0
Interest expense and other, net																		(110,477,000)		(90,054,000)		(88,665,000)
Equity in earnings (loss) of subsidiaries																		(530,697,000)		79,622,000		(380,176,000)
(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix																		(641,174,000)		(10,432,000)		(468,841,000)
Income tax benefit (expense)																		42,180,000		37,228,000		18,316,000
Equity in net (loss) earnings of CareCentrix																				0		0
(Loss) income from continuing operations																		(598,994,000)		26,796,000		(450,525,000)
Discontinued operations, net of tax																						0
Net (loss) income																						(450,525,000)
Less: Net income attributable to noncontrolling interests																		0		0		0
Net (loss) income attributable to Gentiva shareholders																		(598,994,000)		26,796,000		(450,525,000)
Total comprehensive (loss) income																		(598,994,000)		26,796,000		(451,003,000)
Guarantor Subsidiaries [Member]
Condensed Consolidating Statement of Comprehensive Income
Total net revenues																		1,676,888,000		1,666,368,000		1,757,459,000
Cost of services sold																		905,261,000		884,903,000		921,826,000
Gross profit																		771,627,000		781,465,000		835,633,000
Selling, general and administrative expenses																		(682,262,000)		(638,975,000)		(715,343,000)
Dividend income																						8,590,000
Gain on sale of assets and businesses, net																				8,014,000		1,061,000
Goodwill, intangibles and other long-lived asset impairment																		(610,436,000)		(19,132,000)		(643,305,000)
Interest expense and other, net																		0		0		0
Equity in earnings (loss) of subsidiaries																		(4,561,000)		3,038,000		221,000
(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix																		(525,632,000)		134,410,000		(513,143,000)
Income tax benefit (expense)																		(5,065,000)		(52,487,000)		56,637,000
Equity in net (loss) earnings of CareCentrix																				(2,301,000)		68,381,000
(Loss) income from continuing operations																		(530,697,000)		79,622,000		(388,125,000)
Discontinued operations, net of tax																						7,949,000
Net (loss) income																						(380,176,000)
Less: Net income attributable to noncontrolling interests																		0		0		0
Net (loss) income attributable to Gentiva shareholders																		(530,697,000)		79,622,000		(380,176,000)
Total comprehensive (loss) income																		(530,697,000)		79,622,000		(380,176,000)
Non-Guarantor Subsidiaries [Member]
Condensed Consolidating Statement of Comprehensive Income
Total net revenues																		64,989,000		61,656,000		52,404,000
Cost of services sold																		52,152,000		39,058,000		37,714,000
Gross profit																		12,837,000		22,598,000		14,690,000
Selling, general and administrative expenses																		(19,454,000)		(16,791,000)		(15,064,000)
Dividend income																						0
Gain on sale of assets and businesses, net																				0		0
Goodwill, intangibles and other long-lived asset impairment																		0		0		0
Interest expense and other, net																		93,000		107,000		55,000
Equity in earnings (loss) of subsidiaries																		0		0		0
(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix																		(6,524,000)		5,914,000		(319,000)
Income tax benefit (expense)																		2,450,000		(1,992,000)		815,000
Equity in net (loss) earnings of CareCentrix																				0		0
(Loss) income from continuing operations																		(4,074,000)		3,922,000		496,000
Discontinued operations, net of tax																						366,000
Net (loss) income																						862,000
Less: Net income attributable to noncontrolling interests																		(487,000)		(884,000)		(641,000)
Net (loss) income attributable to Gentiva shareholders																		(4,561,000)		3,038,000		221,000
Total comprehensive (loss) income																		(4,074,000)		3,922,000		862,000
Eliminations [Member]
Condensed Consolidating Statement of Comprehensive Income
Total net revenues																		(15,233,000)		(15,220,000)		(11,085,000)
Cost of services sold																		(15,233,000)		(15,220,000)		(11,085,000)
Gross profit																		0		0		0
Selling, general and administrative expenses																		0		0		0
Dividend income																						0
Gain on sale of assets and businesses, net																				0		0
Goodwill, intangibles and other long-lived asset impairment																		0		0		0
Interest expense and other, net																		0		0		0
Equity in earnings (loss) of subsidiaries																		535,258,000		(82,660,000)		379,955,000
(Loss) income from continuing operations before income taxes and equity in net (loss) earnings of CareCentrix																		535,258,000		(82,660,000)		379,955,000
Income tax benefit (expense)																		0		0		0
Equity in net (loss) earnings of CareCentrix																				0		0
(Loss) income from continuing operations																		535,258,000		(82,660,000)		379,955,000
Discontinued operations, net of tax																						0
Net (loss) income																						379,955,000
Less: Net income attributable to noncontrolling interests																		0		0		0
Net (loss) income attributable to Gentiva shareholders																		535,258,000		(82,660,000)		379,955,000
Total comprehensive (loss) income																		$ 535,258,000		$ (82,660,000)		$ 379,955,000

[1] For the year ended December 31, 2011, the Company recognized dividend income of $8.6 million as a result of the sale of a portion of the Company’s combined common and preferred ownership of CareCentrix.

[2] The Company performed its annual impairment test as of December 31, 2013 for its Home Health, Hospice and Community Care segments. Based on this assessment, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $379.8 million and $6.3 million, respectively, for the year 2013.At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit. Based on the results of the interim impairment test, the Company recorded a non-cash impairment charge relating to goodwill of approximately $220.8 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million. In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million. Hospice and corporate assets were reduced by $220.8 million and $3.5 million, respectively, as a result of these impairments.For the year ended December 31, 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name. Home Health and Hospice assets were reduced by $6.0 million and $13.1 million, respectively, as of December 31, 2012 as a result of the impairment.For the year ended December 31, 2011, the Company recorded non-cash impairment charges associated with goodwill, intangibles and other long-lived assets of $643.3 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a significant decline in the price of the Company's common stock during the fiscal year, (iv) a write-down of software and (v) a change in the estimated fair value of real estate. Home Health, Hospice and corporate assets were reduced by $408.4 million, $193.7 million and $41.2 million, respectively, as of December 31, 2011, as a result of the impairment.

[3] For the year ended December 31, 2013, interest expense and other, net included charges of $19.1 million relating to the write-off of deferred debt issuance costs and fees associated with the Company entering a new credit agreement, dated October 18, 2013. For the year ended December 31, 2012, interest expense and other, net included charges of $0.5 million relating to the write-off of deferred debt issuance costs associated with the revolving credit facility. In addition, interest expense and other, net for the year ended December 31, 2011 included charges of $3.8 million associated with terminating the Company’s interest rate swaps in connection with the refinancing of the Company’s Term Loan A and Term Loan B under the Company’s former credit agreement. See Note 12 for additional information.

[4] For the fourth quarter of 2013, the Company recorded non-cash impairment charges relating to the goodwill and intangibles of its Hospice segment of approximately $379.8 million and $6.3 million, respectively, for the year 2013.For the first quarter of 2013, the Company recorded non-cash impairment charges associated with goodwill and other long-lived assets of $224.3 million. This charge was the result of (i) changes in the Company's business climate, (ii) uncertainties around Medicare reimbursement as the federal government worked to reduce the federal deficit, (iii) a write-down of software and (iv) a change in the estimated fair value of real estate. See Notes 8 and 9.For the third quarter of 2012, the Company recorded non-cash impairment charges associated with a write-off of its trade name intangibles of $19.1 million in connection with the Company's initiative to re-brand its operations under the Gentiva name.

[5] For the fourth quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $2.6 million pre-tax gain related to the sale of the Phoenix area hospice operations. For the second quarter of 2012, income (loss) before income taxes and equity in net earnings of CareCentrix, includes a $5.4 million pre-tax gain associated with the sale of (i) the Gentiva consulting business and (ii) the sale of eight home health branches and four hospice branches in Louisiana.

[6] (Loss) income before income taxes and equity in net earnings (loss) of CareCentrix for each of the 2013 and 2012 quarters includes charges relating to cost savings initiatives and other restructuring, integration and acquisition activities and legal settlements as follows (in thousands): FirstQuarter SecondQuarter ThirdQuarter FourthQuarterYear ended December 31, 2013$141 $744 $1,699 $24,955Year ended December 31, 2012$5,391 $25 $53 $201

[7] In anticipation of a settlement of claims alleged by the owner of CareCentrix and working capital adjustments as set forth in the stock purchase agreement, during the fourth quarter of 2012, the Company recorded a $6.5 million adjustment to the seller financing note receivable to reflect its revised estimated fair value of $3.4 million, which is recorded in equity in net loss of CareCentrix.